The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

CML and reoccurring resistance to TKIs

LovelyArley
LovelyArley CSN Member Posts: 2
in Leukemia #1

Hello everyone,

 

I was diagnosed in 2019 and have failed to get my BCR ABL1 to 0.1. I started on Imatinib and then a standard dose of Sprycel. I'm currently on a high dose of sprycel, but my numbers are going up. I was tested for any additional mutations in 2020 (no new mutations or explanations for resistance) and just had the test redone (waiting on results). Depending on what we find I may be switched to Nilotinib. My oncologist has given me until the end of the year before refering me to Stanford or a different health system. I've been taking my medication as prescribed (at the same time daily) and following all diatery restrictions. I'm 26 and female, has this happened to anyone else? How did Nilotinib go for you?

Thanks!

 

Like Care

Discussion Boards